Vanguard Group Inc grew its holdings in Jounce Therapeutics Inc (NASDAQ:JNCE) by 5.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 776,016 shares of the company’s stock after buying an additional 41,945 shares during the period. Vanguard Group Inc owned 2.37% of Jounce Therapeutics worth $5,045,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in JNCE. Millennium Management LLC lifted its position in shares of Jounce Therapeutics by 91.6% in the second quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock valued at $5,202,000 after buying an additional 324,681 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Jounce Therapeutics by 153.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares during the last quarter. BlackRock Inc. lifted its holdings in Jounce Therapeutics by 22.2% during the 2nd quarter. BlackRock Inc. now owns 1,394,905 shares of the company’s stock worth $10,684,000 after purchasing an additional 253,120 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Jounce Therapeutics by 186.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 314,831 shares of the company’s stock worth $2,412,000 after purchasing an additional 204,762 shares during the last quarter. Finally, Bridgeway Capital Management Inc. acquired a new stake in Jounce Therapeutics during the 3rd quarter worth approximately $1,321,000. 82.69% of the stock is owned by institutional investors.
Jounce Therapeutics stock traded up $0.04 during mid-day trading on Tuesday, reaching $4.29. 5,742 shares of the company were exchanged, compared to its average volume of 231,414. Jounce Therapeutics Inc has a 12 month low of $2.66 and a 12 month high of $29.25. The firm has a market cap of $138.00 million, a PE ratio of -7.53 and a beta of 3.80.
Several analysts recently weighed in on JNCE shares. Zacks Investment Research cut Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. Cowen reissued a “hold” rating on shares of Jounce Therapeutics in a report on Tuesday, November 13th. Raymond James dropped their price target on Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Tuesday, October 23rd. HC Wainwright set a $13.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 14th. Finally, JPMorgan Chase & Co. cut Jounce Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Jounce Therapeutics presently has an average rating of “Hold” and a consensus price target of $11.67.
TRADEMARK VIOLATION NOTICE: “Jounce Therapeutics Inc (JNCE) Stake Increased by Vanguard Group Inc” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4146553/jounce-therapeutics-inc-jnce-stake-increased-by-vanguard-group-inc.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
See Also: Consumer Price Index (CPI)
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.